New combo therapy aims to boost survival in tough rectal cancer

NCT ID NCT07549399

Recruiting now Disease control Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This Phase 3 trial tests whether adding immunotherapy and a targeted drug to short-course radiotherapy and chemotherapy improves outcomes for people with high-risk rectal cancer. About 204 participants will receive either the standard treatment or the intensified combo. The study aims to see if the new approach can reduce cancer recurrence and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Short-course radiotherapy, chemotherapy (mFOLFOX6), immunotherapy (PD-1 antibody), and targeted therapy (cetuximab or bevacizumab based on genetic type)
What this could lead to: If successful, this could offer a more effective neoadjuvant treatment for high-risk rectal cancer, potentially improving survival and reducing recurrence.
What could go wrong: This is an early-stage Phase 3 trial with no results yet. The intense combination therapy may cause significant side effects, and benefits over standard care are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Marinesco-Sjogren syndrome rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH-RISK CANCER MSS RECTAL ADENOCARCINOMA

Contacts and locations

Locations

Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 510065, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.